Literature DB >> 10569771

Human opsonins induced during meningococcal disease recognize transferrin binding protein complexes.

A K Lehmann1, A R Gorringe, K M Reddin, K West, I Smith, A Halstensen.   

Abstract

Patient serum opsonins against transferrin binding protein A+B (TbpA+B) complexes from two Neisseria meningitidis strains (K454 and B16B6, with 85- and 68-kDa TbpB, respectively) were quantified by a functional phagocytosis and oxidative burst assay. TbpA+B complexes adsorbed to fluorescent beads were opsonized with individual acute and convalescent sera from 40 patients infected by a variety of meningococcal strains. Flow cytometric quantitation of leukocyte phagocytosis products (PP) demonstrated that disease-induced serum opsonins recognized TbpA+B, and the highest anti-TbpA+B serum opsonic activities were found between admission to hospital and 6 weeks later. The PP values obtained with TbpA+B from strain B16B6 (PP(B16B6)) were higher than those obtained with TbpA+B from strain K454 (PP(K454)), with both acute and convalescent sera (P < 0.0001), and correlated positively with higher immunoglobulin G enzyme-linked immunosorbent assay titers against TbpA+B from strain B16B6 than from strain K454 (P < 0.001). In spite of considerable variations between individuals, significant correlations were found between the PP(B16B6) and PP(K454) values, and the PP values did not depend on the variability of the TbpB proteins of the disease-causing strains. Simultaneously measured oxidative burst activity correlated closely with the PP values. We conclude that highly cross-reactive anti-TbpA+B serum opsonins are produced during meningococcal disease. The anti-TbpA+B opsonic activities were not affected by the variability of the TbpB proteins of the disease-causing strains, which further adds to the evidence for the vaccine potential of meningococcal TbpA+B complexes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10569771      PMCID: PMC97063          DOI: 10.1128/IAI.67.12.6526-6532.1999

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  28 in total

1.  Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway.

Authors:  G Bjune; E A Høiby; J K Grønnesby; O Arnesen; J H Fredriksen; A Halstensen; E Holten; A K Lindbak; H Nøkleby; E Rosenqvist
Journal:  Lancet       Date:  1991-11-02       Impact factor: 79.321

2.  Aspects of the molecular structure of IgG subclasses.

Authors:  D R Burton; L Gregory; R Jefferis
Journal:  Monogr Allergy       Date:  1986

3.  Dihydrorhodamine 123: a new flow cytometric indicator for respiratory burst activity in neutrophil granulocytes.

Authors:  G Rothe; A Oser; G Valet
Journal:  Naturwissenschaften       Date:  1988-07

4.  Serum opsonins to serogroup B meningococci in meningococcal disease.

Authors:  A Halstensen; H Sjursen; S E Vollset; L O Frøholm; A Naess; R Matre; C O Solberg
Journal:  Scand J Infect Dis       Date:  1989

5.  Cross-reacting serum opsonins in patients with meningococcal disease.

Authors:  H K Guttormsen; R Bjerknes; A Naess; V Lehmann; A Halstensen; S Sørnes; C O Solberg
Journal:  Infect Immun       Date:  1992-07       Impact factor: 3.441

6.  Killing of Neisseria meningitidis by human neutrophils: implications for normal and complement-deficient individuals.

Authors:  S C Ross; P J Rosenthal; H M Berberich; P Densen
Journal:  J Infect Dis       Date:  1987-06       Impact factor: 5.226

Review 7.  Infectious diseases associated with complement deficiencies.

Authors:  J E Figueroa; P Densen
Journal:  Clin Microbiol Rev       Date:  1991-07       Impact factor: 26.132

8.  Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease.

Authors:  J H Fredriksen; E Rosenqvist; E Wedege; K Bryn; G Bjune; L O Frøholm; A K Lindbak; B Møgster; E Namork; U Rye
Journal:  NIPH Ann       Date:  1991-12

Review 9.  Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications.

Authors:  J G van de Winkel; P J Capel
Journal:  Immunol Today       Date:  1993-05

10.  Human monoclonal antibody with protective activity for Escherichia coli K1 and Neisseria meningitidis group B infections.

Authors:  H V Raff; D Devereux; W Shuford; D Abbott-Brown; G Maloney
Journal:  J Infect Dis       Date:  1988-01       Impact factor: 5.226

View more
  12 in total

1.  Protection by meningococcal outer membrane protein PorA-specific antibodies and a serogroup B capsular polysaccharide-specific antibody in complement-sufficient and C6-deficient infant rats.

Authors:  Maija Toropainen; Leena Saarinen; Gestur Vidarsson; Helena Käyhty
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

Review 2.  The immunopathogenesis of meningococcal disease.

Authors:  A J Kvalsvig; D J Unsworth
Journal:  J Clin Pathol       Date:  2003-06       Impact factor: 3.411

3.  Immunogenicity of gonococcal transferrin binding proteins during natural infections.

Authors:  Gregory A Price; Marcia M Hobbs; Cynthia Nau Cornelissen
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

4.  Functional opsonic activity of human serum antibodies to inner core lipopolysaccharide (galE) of serogroup B meningococci measured by flow cytometry.

Authors:  J S Plested; B L Ferry; P A Coull; K Makepeace; A K Lehmann; F G MacKinnon; H G Griffiths; M A Herbert; J C Richards; E R Moxon
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

5.  Strategy to create chimeric proteins derived from functional adhesin regions of Mycoplasma pneumoniae for vaccine development.

Authors:  Nicol Schurwanz; Enno Jacobs; Roger Dumke
Journal:  Infect Immun       Date:  2009-08-10       Impact factor: 3.441

6.  Seroprevalence of Antibody-Mediated, Complement-Dependent Opsonophagocytic Activity against Neisseria meningitidis Serogroup B in England.

Authors:  Holly E Humphries; Charlotte Brookes; Lauren Allen; Eeva Kuisma; Andrew Gorringe; Stephen Taylor
Journal:  Clin Vaccine Immunol       Date:  2015-03-04

7.  Allelic diversity of the two transferrin binding protein B gene isotypes among a collection of Neisseria meningitidis strains representative of serogroup B disease: implication for the composition of a recombinant TbpB-based vaccine.

Authors:  B Rokbi; G Renauld-Mongenie; M Mignon; B Danve; D Poncet; C Chabanel; D A Caugant; M J Quentin-Millet
Journal:  Infect Immun       Date:  2000-09       Impact factor: 3.441

8.  Protective antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed genome-derived neisserial antigen 1870.

Authors:  Victor C Hou; Oliver Koeberling; Jo Anne Welsch; Dan M Granoff
Journal:  J Infect Dis       Date:  2005-07-15       Impact factor: 5.226

Review 9.  Meningococcal vaccines.

Authors:  Jens U Rüggeberg; Andrew J Pollard
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

10.  Immunity to Neisseria meningitidis group B in adults despite lack of serum bactericidal antibody.

Authors:  Jo Anne Welsch; Dan Granoff
Journal:  Clin Vaccine Immunol       Date:  2007-10-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.